Aligos Therapeutics Inc (ALGS)

Dec 21, 2024

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week - Yahoo Finance

Dec 21, 2024

Dec 21, 2024

Charles Schwab Investment Management Inc. Lowers Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World

Dec 21, 2024

Dec 20, 2024

Anavex Life Sciences (NASDAQ:AVXL) vs. Aligos Therapeutics (NASDAQ:ALGS) Head to Head Analysis - Defense World

Dec 20, 2024

Dec 16, 2024

Aligos Therapeutics stock soars to 52-week high of $35.47 - Investing.com

Dec 16, 2024

Dec 13, 2024

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 13, 2024

Dec 11, 2024

Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks (NASDAQ:ALGS) - Seeking Alpha

Dec 11, 2024

Dec 09, 2024

How To Trade (ALGS) - Stock Traders Daily

Dec 09, 2024

Dec 06, 2024

Aligos stock hits 52-week high at $30.01 amid robust gains - Investing.com India

Dec 06, 2024

Dec 02, 2024

Baker BROS. Advisors LP Decreases Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - MarketBeat

Dec 02, 2024

Nov 30, 2024

Aligos Therapeutics Inc (ALGS) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register

Nov 30, 2024

Nov 28, 2024

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 140.3% in November - MarketBeat

Nov 28, 2024

Nov 27, 2024

Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth? - Simply Wall St

Nov 27, 2024

Nov 26, 2024

Aligos Therapeutics to Present at Investor Conferences in December - The Manila Times

Nov 26, 2024

Nov 26, 2024

Aligos Therapeutics to Present at Two Major Healthcare Investor Conferences in December | ALGS Stock News - StockTitan

Nov 26, 2024

Nov 22, 2024

Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail

Nov 22, 2024

Nov 20, 2024

Aligos Therapeutics files $400M mixed securities shelf - MSN

Nov 20, 2024

Nov 20, 2024

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024

Nov 20, 2024

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - The Manila Times

Nov 20, 2024

Nov 19, 2024

Aligos Reports 100% HBV Suppression Success, Strong MASH Treatment Results in Clinical Trials | ALGS Stock News - StockTitan

Nov 19, 2024

Nov 15, 2024

EcoR1 Capital, LLC Increases Stake in Aligos Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Expands Stake in Aligos Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Compass Therapeutics Inc (CMPX) Quarterly 10-Q Report - Quartzy

Nov 14, 2024

Nov 14, 2024

Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Expands By 46.5% - MarketBeat

Nov 14, 2024

Nov 13, 2024

Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail

Nov 13, 2024

Nov 12, 2024

Aligos Therapeutics Inc (ALGS) Quarterly 10-Q Report - Quartzy

Nov 12, 2024

Nov 11, 2024

United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com

Nov 11, 2024

Nov 11, 2024

U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn

Nov 11, 2024

Nov 11, 2024

Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC Wainwright - Defense World

Nov 11, 2024

Nov 10, 2024

Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations - Yahoo Canada Finance

Nov 10, 2024

Nov 08, 2024

(ALGS) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 08, 2024

Nov 07, 2024

Aligos Therapeutics Reports Q3 2024 Progress - TipRanks

Nov 07, 2024

Nov 07, 2024

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024

Nov 06, 2024

Aligos Reports 46% Liver Fat Reduction in MASH Trial; Q3 Loss Widens to $19.3M | ALGS Stock News - StockTitan

Nov 06, 2024

Oct 31, 2024

Aligos planning for Phase 2 trial of treatment for hepatitis B - Liver Disease News

Oct 31, 2024

Oct 30, 2024

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 - StockTitan

Oct 30, 2024

Oct 29, 2024

Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal

Oct 29, 2024

Oct 28, 2024

(ALGS) On The My Stocks Page - Stock Traders Daily

Oct 28, 2024

Oct 27, 2024

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short Interest - MarketBeat

Oct 27, 2024

Oct 27, 2024

Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% – Here’s What Happened - Defense World

Oct 27, 2024

Oct 25, 2024

Aligos Therapeutics (NASDAQ:ALGS) Trading Down 5.4%Here's What Happened - MarketBeat

Oct 25, 2024

Oct 25, 2024

HC Wainwright Reiterates Buy Rating for Aligos Therapeutics (NASDAQ:ALGS) - Defense World

Oct 25, 2024

Oct 24, 2024

Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat

Oct 24, 2024

Oct 23, 2024

Aligos Therapeutics' (ALGS) Buy Rating Reiterated at HC Wainwright - MarketBeat

Oct 23, 2024

Oct 22, 2024

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 - The Manila Times

Oct 22, 2024

Oct 18, 2024

Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH) - 2 Minute Medicine

Oct 18, 2024

Oct 15, 2024

Aligos Therapeutics (NASDAQ:ALGS) Shares Gap UpWhat's Next? - MarketBeat

Oct 15, 2024

Oct 15, 2024

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 202 - The Manila Times

Oct 15, 2024